Aridis to delist from Nas­daq; Bi­cy­cle clos­es $200M+ of­fer­ing

Aridis Phar­ma­ceu­ti­cals is be­ing tak­en off the Nas­daq, ef­fec­tive Wednes­day.

The biotech re­port­ed the news in an SEC fil­ing Mon­day, say­ing that it will be delist­ed from the Nas­daq Cap­i­tal Mar­ket once the mar­ket opens on Ju­ly 19th and that its stock will be trad­ed on OTC Pink Sheets.

The delist­ing comes as the com­pa­ny an­nounced Mon­day af­ter­noon that it had re­ceived pos­i­tive feed­back from the EMA on run­ning a Phase III tri­al for its can­di­date AR-301, a mon­o­clon­al an­ti­body that it is de­vel­op­ing as an ad­junc­tive with stan­dard of care for a spe­cif­ic type of pneu­mo­nia. AR-301 failed a Phase III ear­li­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER